Clinical role of serum programmed death ligand 1 in patients with hepatocellular carcinoma: Where does it come from?
Hatem A ElmezayenHirohisa OkabeYoshifumi BabaToshihiko YusaRumi ItoyamaYosuke NakaoTakanobu YamaoNaoki UmzakiMasayo TsukamotoYuki KitanoTatsunori MiyataKota ArimaHiromitsu HayashiKatsunori ImaiAkira ChikamotoYo-Ichi YamashitaHideo BabaPublished in: Surgery today (2019)
PD-L1-expressing cells in the background liver, but not in the tumor tissue, appeared to contribute to the sPD-L1 level. The sPD-L1 level may thus not indicate the tumor burden in patients with HCC.